Business Description
Spago Nanomedical AB
ISIN : SE0004899474
Total Employee Number:
5Compare
Compare
Traded in other countries / regions
SPAGO.Sweden7UX.Germany IPO Date
2021-03-31Description
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.8 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.07 | |||||
Beneish M-Score | 0.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -55 | |||||
3-Year EBITDA Growth Rate | 44.4 | |||||
3-Year EPS without NRI Growth Rate | 44.9 | |||||
3-Year FCF Growth Rate | 44.4 | |||||
3-Year Book Growth Rate | -68.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -23.11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -37.62 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.63 | |||||
9-Day RSI | 48.83 | |||||
14-Day RSI | 49.53 | |||||
3-1 Month Momentum % | -6.52 | |||||
6-1 Month Momentum % | -17.31 | |||||
12-1 Month Momentum % | -57.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.58 | |||||
Quick Ratio | 5.58 | |||||
Cash Ratio | 4.9 | |||||
Days Sales Outstanding | 83.46 | |||||
Days Payable | 72.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -70.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -9801.65 | |||||
Operating Margin % | -21804.13 | |||||
Net Margin % | -21419.01 | |||||
EBITDA Margin % | -21585.12 | |||||
FCF Margin % | -22960 | |||||
OCF Margin % | -22960 | |||||
ROE % | -116.26 | |||||
ROA % | -93.77 | |||||
ROIC % | -761.68 | |||||
3-Year ROIIC % | -8.94 | |||||
ROC (Joel Greenblatt) % | -12722.6 | |||||
ROCE % | -114.1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 112.01 | |||||
PB Ratio | 3.11 | |||||
EV-to-EBIT | -2.33 | |||||
EV-to-Forward-EBIT | 5.18 | |||||
EV-to-EBITDA | -2.34 | |||||
EV-to-Forward-EBITDA | 6.62 | |||||
EV-to-Revenue | 505.86 | |||||
EV-to-Forward-Revenue | 3.43 | |||||
EV-to-FCF | -2.46 | |||||
Earnings Yield (Greenblatt) % | -42.92 | |||||
FCF Yield % | -27.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spago Nanomedical AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.01 | ||
| EPS (TTM) (€) | -0.004 | ||
| Beta | 2.1751 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.45 | ||
| Volatility % | 99.57 | ||
| 14-Day RSI | 49.53 | ||
| 14-Day ATR (€) | 0.004075 | ||
| 20-Day SMA (€) | 0.00913 | ||
| 12-1 Month Momentum % | -57.39 | ||
| 52-Week Range (€) | 0.0042 - 0.022104 | ||
| Shares Outstanding (Mil) | 798.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spago Nanomedical AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spago Nanomedical AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 99 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 22 days | ||
| General meeting for 2026 | 2026-06-10 15:00 | 0.01 (+76.00%) | ||
| Annual report for 2025 | 2026-05-19 | 0.01 (+64.52%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 0.01 (+73.33%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-05 | 0.01 (+88.89%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 0.01 (-8.89%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 0.02 (+30.49%) | ||
| General meeting for 2025 | 2025-05-14 | 0.01 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-07 | 0.01 (+0.00%) |
Show
Entries
Spago Nanomedical AB Frequently Asked Questions
What is Spago Nanomedical AB(FRA:7UX)'s stock price today?
The current price of FRA:7UX is €0.01. The 52 week high of FRA:7UX is €0.02 and 52 week low is €0.00.
When is next earnings date of Spago Nanomedical AB(FRA:7UX)?
The next earnings date of Spago Nanomedical AB(FRA:7UX) is 2026-08-20.
Does Spago Nanomedical AB(FRA:7UX) pay dividends? If so, how much?
Spago Nanomedical AB(FRA:7UX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Spago Nanomedical AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers